| Correlations of telomere length, telomerase activity, and telomeric-repeat binding factor 1 expression in colorectal carcinoma. | |
| | |
MedLine Citation:
|
PMID: 16388518 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Telomere maintenance has been proposed as an essential step for tumor cell immortalization. The objectives of the current study were to investigate the mechanisms implicated in telomere length in colorectal carcinoma (CRC) and to evaluate the prognostic impact of telomere status. METHODS: Ninety-one colorectal carcinoma samples that were obtained from patients who underwent surgery were analyzed to investigate the factors related to telomere function. The authors studied telomerase activity, terminal restriction fragment (TRF) length, and telomeric-repeat binding factor (TRF1) expression and analyzed the prognostic implications of those factors. RESULTS: Most tumors (81.3%) displayed telomerase activity. Overall, telomeres in CRC specimens were significantly shorter compared with telomeres in normal, adjacent specimens (P=0.02). Moreover, tumors that demonstrated shortened telomeres displayed higher TRF1 levels than tumors without telomere shortening. In relation to patient prognosis, a significantly poor clinical course was observed in the group of patients who had tumors with longer telomeres (P=0.02), and this finding emerged as an independent prognostic factor in a Cox proportional hazards model (P=0.04; relative risk, 6.48). Among patients with tumors classified as telomerase-positive, telomere length ratios (the ratio of tumor tissues to normal tissues)<or=0.66 or TRF1 over-expression conferred a favorable outcome (P=0.03 and P=0.05, respectively). CONCLUSIONS: The majority of CRC specimens in the current study displayed telomerase reactivation. However, only those tumors that displayed telomere elongation conferred a poor prognosis. Conversely, colorectal tumors that over-expressed TRF1 demonstrated telomere shortening, and patients with those tumors had a better clinical course. |
| | |
Authors:
|
Cristina Garcia-Aranda; Carmen de Juan; Antonio Diaz-Lopez; Andres Sanchez-Pernaute; Antonio-Jose Torres; Eduardo Diaz-Rubio; Jose-Luis Balibrea; Manuel Benito; Pilar Iniesta |
Related Documents
:
|
22121438 - Gastrointestinal stromal tumor causing ileo-ileal intussusception in an adult patient a... 15580218 - Abnormal production of tumor necrosis factor (tnf) -- alpha and clinical efficacy of th... 19339578 - Telomere-maintenance mechanisms in soft-tissue malignant fibrous histiocytomas. 20214618 - Mechanisms of tumor cell necrosis. 15680748 - A theoretical approach to choosing the minimum number of multiple tumors required for a... 20860838 - P190b rhogap has pro-tumorigenic functions during mmtv-neu mammary tumorigenesis and me... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Cancer Volume: 106 ISSN: 0008-543X ISO Abbreviation: Cancer Publication Date: 2006 Feb |
Date Detail:
|
Created Date: 2006-01-26 Completed Date: 2006-03-14 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0374236 Medline TA: Cancer Country: United States |
Other Details:
|
Languages: eng Pagination: 541-51 Citation Subset: AIM; IM |
Copyright Information:
|
Copyright (c) 2005 American Cancer Society. |
Affiliation:
|
Departamento de Bioquimica y Biologia Molecular, Facultad de Farmacia, Universidad Complutense, Madrid, Spain. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Carcinoma / genetics*, metabolism, pathology Colorectal Neoplasms / genetics*, metabolism, pathology Female Humans Male Middle Aged Prognosis Risk Factors Survival Analysis Telomerase / metabolism* Telomere / ultrastructure* Telomeric Repeat Binding Protein 1 / biosynthesis* |
| Chemical | |
Reg. No./Substance:
|
0/Telomeric Repeat Binding Protein 1; EC 2.7.7.49/Telomerase |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Phosphodiesterase 5 (PDE 5) inhibitors for the treatment of male erectile disorder: attaining select...
Next Document: Gonadotropin-releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and...